Roche Holding (RHHBY)
(Delayed Data from OTC)
$41.70 USD
-0.04 (-0.10%)
Updated Aug 28, 2024 04:00 PM ET
2-Buy of 5 2
B Value C Growth B Momentum B VGM
Price, Consensus and EPS Surprise
RHHBY 41.70 -0.04(-0.10%)
Will RHHBY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RHHBY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RHHBY
Roche Obtains Approval For its Rare Blood Disorder Drug in the EU
Here's Why You Should Consider Buying Akebia (AKBA) Stock
RHHBY: What are Zacks experts saying now?
Zacks Private Portfolio Services
J&J (JNJ) Gets EU Approval for Bladder Cancer Drug Balversa
All You Need to Know About Roche Holding (RHHBY) Rating Upgrade to Strong Buy
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
Other News for RHHBY
Truist biotech analysts hold an analyst/industry conference call
Roche gets the nod from EU for PiaSky in rare blood condition
Roche announces PiaSky approved in EU for people with PNH
Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
Tonix stock jumps on collaboration for mpox vaccine candidate